Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 5/20 | 0.45 |
| ▸ | NOS1 | P29475 | 4/20 | 0.44 |
| ▸ | NOS3 | P29474 | 2/20 | 0.44 |
| ▸ | CDK2 | P24941 | 4/20 | 0.43 |
| ▸ | CDK1 | P06493 | 3/20 | 0.43 |
| ▸ | CDK4 | P11802 | 3/20 | 0.43 |
| ▸ | CCND1 | P24385 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4895415 | 1.00 | MAP4K4 (0.47) | MAP4K4NOS2NOS1NOS3CDK2 | |
| SCHEMBL7154085 | 0.80 | CDK1 (0.38) | MAP4K4CDK2CDK1CDK4CCND1 | |
| Hydrochloric Acid SCHEMBL4892763 | 0.79 | MAPKAPK2 (0.50) | ALDH1A1HSD17B10SMN1; SMN2KDM4ENPC1 | |
| Hydrochloric Acid SCHEMBL4892770 | 0.79 | MAPKAPK2 (0.50) | ALDH1A1HSD17B10SMN1; SMN2KDM4ENPC1 | |
| SCHEMBL7154151 | 0.76 | PIM1 (0.38) | CDK1ALDH1A1 | |
| SCHEMBL7154149 | 0.76 | PIM1 (0.38) | CDK1ALDH1A1 | |
| SCHEMBL7154060 | 0.76 | HRH3 (0.46) | SMN1; SMN2KDM4ERAB9ALMNAMAPT | |
| Hydrochloric Acid SCHEMBL4898626 | 0.75 | PIM1 (0.37) | CDK1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4898605 | 0.75 | PIM1 (0.37) | CDK1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4889879 | 0.75 | HRH3 (0.45) | SMN1; SMN2KDM4ERAB9ALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7041824-B2 | Purine derivatives, preparation method and use as medicines | AVENTIS PHARMA S.A. (FR) | 2006-05-09 | — | — | US | claimed |
| US-20040063732-A1 | Novel purine derivatives, preparation method and use as medicines | AVENTIS PHARMA S.A. (FR) | 2004-04-01 | — | — | US | claimed |
| EP-1347975-A1 | NOVEL PURINE DERIVATIVES, PREPARATION METHOD AND USE AS MEDICINES | Aventis Pharma S.A. (FR) | 2003-10-01 | — | — | EP | claimed |
| WO-2002051843-A1 | NOVEL PURINE DERIVATIVES, PREPARATION METHOD AND USE AS MEDICINES | AVENTIS PHARMA S.A. (FR) | 2002-07-04 | — | — | WO | claimed |
| US-20080090849-A1 | NOVEL PURINE DERIVATIVES, PREPARATION METHOD AND USE AS MEDICINES | AVENTIS PHARMA S.A. (FR) | 2008-04-17 | — | — | US | disclosed |
| US-7041824-B2 | Purine derivatives, preparation method and use as medicines | AVENTIS PHARMA S.A. (FR) | 2006-05-09 | — | — | US | disclosed |
| US-20040063732-A1 | Novel purine derivatives, preparation method and use as medicines | AVENTIS PHARMA S.A. (FR) | 2004-04-01 | — | — | US | disclosed |
| EP-1347975-A1 | NOVEL PURINE DERIVATIVES, PREPARATION METHOD AND USE AS MEDICINES | Aventis Pharma S.A. (FR) | 2003-10-01 | — | — | EP | disclosed |
| WO-2002051843-A1 | NOVEL PURINE DERIVATIVES, PREPARATION METHOD AND USE AS MEDICINES | AVENTIS PHARMA S.A. (FR) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063732-A1 | Novel purine derivatives, preparation method and use as medicines | CDK1, CDK6, PNP | MAP4K4 238/4885NOS2 1475/4885NOS1 969/4885 |
| US-20080090849-A1 | NOVEL PURINE DERIVATIVES, PREPARATION METHOD AND USE AS MEDICINES | CDK1, CDK6, PNP | MAP4K4 224/4885NOS2 1678/4885NOS1 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.